Group 1 - Meilixin plans to raise no more than 1.2 billion yuan for semiconductor equipment precision components, communication and automotive parts projects, and to supplement working capital [2] - Olin Bio has prepaid corporate income tax totaling 4.2001 million yuan, with no penalties from tax authorities [3] - Haisen Pharmaceutical's directors and executives plan to reduce their holdings by no more than 124,300 shares, accounting for 0.0816% of the total share capital [4] Group 2 - Aibulu intends to sell 47.4% and 31.6% stakes in its subsidiary Jinque Agriculture for a total of 12.3914 million yuan [5] - Chaoying Electronics plans to increase its Thai subsidiary's capital by 100 million USD for AI high-end PCB expansion [6] - Bona Film Group states that the box office revenue for "Avatar 3" is difficult to predict and the investment return rights are low [7] Group 3 - Junya Technology's PCB products for humanoid robots contribute less than 0.05% to its revenue [9] - Aerospace Electromechanical confirms that its main business does not involve commercial aerospace [10] - Deyi Culture's major shareholder plans to reduce holdings by no more than 2% of shares [11] Group 4 - China National Materials International signed a 2.7 billion yuan engineering contract for a molybdenum mining project [12] - Weiguang Bio plans to sign a 1.13 billion yuan technology cooperation contract for blood products [13] - Suhao Huihong intends to swap assets with its controlling shareholder for a 2.33% stake in Zijin Property Insurance [14] Group 5 - Haike Xinyuan's employee strategic placement plan intends to reduce holdings by no more than 2.5% of shares [15][16] - Taihao Technology's vice president resigns for personal reasons [17] - Huazhu Gaoke plans to establish a joint venture for 3D printing services with a total investment of 100 million yuan [18] Group 6 - Hubei Energy's November power generation was 2.617 billion kWh, a decrease of 17.94% year-on-year [19] - Dong'a Ejiao plans to repurchase shares worth 100 million to 200 million yuan for capital reduction [20] - Longjiang Transportation's shareholder reduced holdings by 1.2% [21] Group 7 - Feilu Co. plans to reduce holdings by no more than 1.02% of shares [22] - Zhongwei Electronics is planning a change in control, leading to a temporary stock suspension [23] - Zhongheng Group's subsidiary received approval for clinical trials of a new cancer drug [24] Group 8 - Guanzhong Ecology's controlling shareholder changed to Deep Blue Financial Whale [25] - Shennong Seed Industry is transferring a 3.8% stake in a subsidiary for 31.9827 million yuan [26] - Sun Cable's major shareholder plans to reduce holdings by no more than 3% of shares [27] Group 9 - Aiwei Electronics' application for issuing convertible bonds has been approved by the Shanghai Stock Exchange [28] - Chongqing Water intends to acquire wastewater treatment projects for 255 million yuan [29] - Boyun New Materials plans to increase its subsidiary's capital by 285 million yuan through debt-to-equity conversion [30] Group 10 - Zhongbai Group is closing unprofitable stores, expecting a loss of approximately 180 million yuan [31] - Changyuan Power's November power generation decreased by 17.88% year-on-year [32]

Key Points - Junya Technology's PCB products can be used in humanoid robots, but these products account for a very small proportion of the company's revenue [1] - Aerospace Machinery's main business does not involve commercial aerospace [1] - Xinhua Co. plans to invest 153 million yuan in the second phase of its synthetic flavor product base [1] - China National Petroleum plans to acquire 100% equity of three gas storage companies for 40 billion yuan [1] - Dong'e Ejiao intends to repurchase shares worth 100 million to 200 million yuan [1] - Haike New Source Asset Management plans to reduce its holdings by no more than 2.5% [2] - Meilixin plans to raise no more than 1.2 billion yuan for the construction of precision structural components for semiconductor equipment [2] - Huazhong Xinchuang received project designation notification from Beiqi Foton [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000423 证券简称：东阿阿胶 公告编号：2025-71 东阿阿胶股份有限公司 第十一届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 1．东阿阿胶股份有限公司（以下简称"公司"）第十一届董事会第十五次会议，根据公司《董事会议事 规则》等相关规定，全体董事同意豁免本次会议通知时间要求,于2025年12月4日以邮件方式发出会议通 知。 2．本次董事会会议，于2025年12月4日以通讯表决方式召开。 3．会议应出席会议董事8人，实际出席会议董事8人。 4．本次董事会会议的召开，符合有关法律、行政法规、部门规章、规范性文件和公司章程等规定。 二、董事会会议审议情况 本次会议审议并通过了以下议案： 1．《关于以集中竞价交易方式回购公司股份方案的议案》 （1）回购股份的目的 基于对未来发展的信心和对公司内在价值的认可，为维护广大投资者利益、增强投资者信心，进一步提 升公司价值，在综合考虑公司经营情况和财务状况的基础上，公司拟以自有资金或自筹资金，通过二级 市 ...

Group 1 - Company Guanzhong Ecological has changed its controlling shareholder to Deep Blue Whale, with the first phase of share transfer completed involving 14.70 million shares at a price of 15 CNY per share, totaling 221 million CNY [2][3] Group 2 - Company Xingfa Group's subsidiary has signed a processing agreement with Qinghai Fudi to produce 80,000 tons per year of lithium iron phosphate, which is expected to enhance the company's market position in the new energy sector [4] Group 3 - Company Meilixin plans to raise up to 1.2 billion CNY through a private placement, with funds allocated for semiconductor equipment projects and working capital [6] Group 4 - Company Dong'e Ejiao intends to repurchase shares worth between 100 million to 200 million CNY, with a maximum repurchase price of 72.08 CNY per share [8] Group 5 - Company Zhongbai Group has closed 30 underperforming stores to optimize its operations, expecting a one-time loss of approximately 180 million CNY from these closures [12] Group 6 - Company Jinxinnong reported sales of 156,800 pigs in November 2025, generating revenue of 115 million CNY, with an average selling price of 12.13 CNY per kilogram for commercial pigs [12] Group 7 - Company Naxinwei is in the process of applying for H-share issuance and listing on the Hong Kong Stock Exchange, with a final share price set at 116 HKD [18]

Core Viewpoint - Dong'e Ejiao plans to repurchase A-shares with a total fund of between 100 million and 200 million yuan, marking the first share buyback and cancellation since its listing, aimed at enhancing investor confidence and recognizing the company's intrinsic value [1][2]. Group 1: Share Buyback Details - The repurchase price ceiling is set at 72.08 yuan per share, which is 150% of the average trading price over the previous 30 trading days [1]. - The estimated number of shares to be repurchased ranges from 1.3873 million to 2.7747 million, accounting for 0.22% to 0.43% of the current total share capital of 643,976,824 shares [1]. - The buyback period will last up to 12 months from the date of shareholder approval, with the board having the discretion to adjust the plan based on market conditions [1]. Group 2: Financial Position - As of September 30, 2025, Dong'e Ejiao's total assets are 12.749 billion yuan, with equity attributable to shareholders at 9.948 billion yuan and current assets at 9.823 billion yuan [2]. - The maximum repurchase amount of 200 million yuan represents only 1.57% of total assets, 2.01% of equity, and 2.04% of current assets, indicating a minimal impact on the company's financial health [2]. - The company asserts that the buyback will not significantly affect its daily operations, financial status, or future development [2]. Group 3: Business Performance and Strategy - Dong'e Ejiao reported a revenue of 4.766 billion yuan for the first three quarters of 2025, a year-on-year increase of 4.41%, with a net profit of 1.274 billion yuan, reflecting a growth of 10.53% [2]. - The company has maintained a high cash dividend policy, ranking first in the cash dividend payment rate among listed companies, with cumulative dividends exceeding 10 billion yuan since its listing [3]. - In 2025, Dong'e Ejiao made significant acquisitions, including a 70% stake in Ma Ji Pharmaceutical and an 80% stake in Alashan Corgoni Group, aiming to expand its product offerings in the male health supplement market [3].

| 1 | 6沃科技 | 实控人张友君的控股企业增持2.63万股公司股票 | | --- | --- | --- | | 2 | 东阿阿胶 | 拟1亿元-2亿元回购股份用于注销 | | | | 12.4上市公司盘后减持情况 | | 1 | 海珠约V | 董事、 高管拟合计减持不超0.0816%股份 | | 2 | 海科新源 | 董事、股东减持公司股份 | | 3 | ST瑞和 | 高管计划减持不超5.25万股 | | 4 | 联动科技 | 控股股东、实际控制人11月28日至12月3日减持38.2万股 | | 5 | 深科技 | 高管钟彦拟减持不超0.0014%股份 | | 6 | 德艺文创 | 股东吴体芳拟减持不超2%股份 | | 1 | 太阳电缆 | 第三大股东象屿集团及其一致行动人拟合计减持不超3%股份 | | 8 | 东望时代 | 股东新岭科技计划减持不超1.20%股份 | | g | 中自科技 | 股东银鞍岭英减持1.00%股份计划完成 | 据统计，12月4日，盘后飞沃科技、东阿阿胶披露增持情况。包括海森药业、海科新源、ST瑞和、联动 科技、深科技、德艺文创、太阳电缆、中自科技、东望时代在内的9家A股 ...

证券日报网讯 12月4日晚间，东阿阿胶发布公告称，公司拟以集中竞价交易方式回购股份，回购金额不 超过20，000万元（含）、不低于10，000万元（含），回购价格不超过72.08元/股，回购股份将用于注 销并减少注册资本，回购期限自股东会审议通过之日起不超过12个月，资金来源为公司自有资金或自筹 资金。 （文章来源：证券日报） ...

Core Viewpoint - Dong'e Ejiao plans to repurchase shares worth 100 million to 200 million yuan, marking its first share buyback since listing, aimed at enhancing shareholder value through share cancellation and improving financial metrics [1] Group 1: Share Buyback and Financial Strategy - The repurchased shares will be used for capital reduction, directly enhancing earnings per share and return on equity [1] - Since 2025, Dong'e Ejiao's total dividends and buyback amounts have exceeded 1.8 billion yuan, showcasing a strong commitment to shareholder returns [1] - The company has maintained a high cash dividend ratio, with cumulative dividends surpassing 10 billion yuan, positioning it favorably within the consumer sector and A-share market [1] Group 2: Financial Performance - In the first three quarters of this year, Dong'e Ejiao reported a net cash flow from operating activities greater than 1, supporting its ongoing dividend and buyback initiatives [2] - The company achieved a revenue of 1.716 billion yuan in Q3, reflecting an 8.5% year-on-year increase, and a net profit of 456 million yuan, up 10.27% [2] - The product portfolio includes core items like Ejiao blocks and compound Ejiao syrup, with a diversified product system driving growth [2] Group 3: Market and Industry Trends - The recovery of the pharmacy channel and the end of industry adjustments provide a favorable sales environment for Dong'e Ejiao [2] - The company has expanded its online sales through e-commerce and live streaming, increasing its revenue share from digital channels [3] - National policies promoting consumption are expected to benefit the food, beverage, and health sectors, positioning Dong'e Ejiao to capitalize on demand growth [3] - Stable medical insurance and centralized procurement policies create a supportive environment for traditional Chinese medicine companies, enhancing market opportunities for Dong'e Ejiao [3]

北京商报讯（记者 王寅浩 宋雨盈）12月4日，东阿阿胶发布公告称，由于个人原因，孙晓波申请辞去公 司第十一届董事会独立董事职务，同时辞去第十一届董事会薪酬与考核委员会主任委员、提名委员会委 员、审计委员会委员等职务。辞职后，孙晓波将不再担任公司及公司控股子公司任何职务。 ...

Core Viewpoint - Dong'e Ejiao Co., Ltd. has announced a significant stock buyback plan of 100-200 million yuan, marking its first-ever share repurchase and cancellation, aimed at enhancing earnings per share and reflecting confidence in future growth [2][3] Group 1: Shareholder Return and Financial Performance - The company has maintained a high cash dividend policy since its listing, with cumulative dividends exceeding 10 billion yuan and a consistent 100% payout ratio, showcasing its strong cash flow and commitment to shareholder interests [2][3] - The stock buyback plan is expected to improve key financial metrics such as earnings per share and return on equity, contributing to a total shareholder return exceeding 1.8 billion yuan by 2025 through a combination of high dividends and share repurchase [3] - Dong'e Ejiao's third-quarter report indicates a stable cash flow with a net cash flow from operating activities greater than 1, supporting both dividends and buybacks, which highlights the sustainability of its shareholder returns [4] Group 2: Market Position and Industry Context - The company is experiencing a notable trend of shareholder concentration, with a slight decrease in the number of shareholders, indicating a narrowing of market divergence and a potential signal for long-term investors [4][5] - Despite the industry being in a recovery phase, Dong'e Ejiao has shown approximately 10% growth in revenue and net profit for the first three quarters, with a gross margin of 73.69%, reflecting strong operational performance [4][6] - The company is well-positioned in the herbal medicine sector, benefiting from brand strength and product barriers, with a diversified product matrix that includes core products like Ejiao blocks and compound Ejiao syrup [6][7] Group 3: Policy Environment and Future Outlook - Recent consumer stimulus policies and a more favorable environment for traditional Chinese medicine are expected to boost demand for Dong'e Ejiao's products, enhancing its growth prospects [7][8] - The easing of price pressure from centralized procurement policies is likely to benefit the company, allowing it to capture a larger market share and improve profitability [7] - Dong'e Ejiao is anticipated to leverage its first-mover advantage in the recovery of the consumer sector, positioning itself as a strong candidate for investment as market opportunities emerge [8]